...
机译:Frontline Bortezomib和Rituximab用于治疗新诊断的高肿瘤负担惰性非霍奇金淋巴瘤:多期一期II研究
Division of Hematology/Oncology Tufts Medical Center Boston MA United States;
Cleveland Clinic Cleveland OH United States;
Division of Hematology-Oncology Department of Medicine Sylvester Comprehensive Cancer Center;
Department of Preventive Medicine Northwestern University Chicago IL United States;
Fox Chase Cancer Center Philadelphia PA United States;
Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University;
Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University;
Feinberg School of Medicine Robert H. Lurie Comprehensive Cancer Center Northwestern University;
Bortezomib; Cancer; Follicular lymphoma; Prognosis; Treatment;
机译:Frontline Bortezomib和Rituximab用于治疗新诊断的高肿瘤负担惰性非霍奇金淋巴瘤:多期一期II研究
机译:在先进,新诊断的和复发/难治性露天性露床细胞和惰性淋巴瘤中的硼替佐米
机译:前线Rituximab,环磷酰胺,多柔比星和泼尼松(VR-Cap)或vincristine(r-chec)在新诊断的甲状腺细胞淋巴瘤患者的子集中,有资格在随机分组,第3阶段3002研究中进行的患者中的疗效和安全性
机译:风险适应的静脉内莫尔甘蔗用佐剂沙利度胺和地塞米松,用于新诊断的未经治疗的全身淀粉样蛋白症患者:II期试验的中期报告
机译:免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性:RU051417I-R-ICE(利妥昔单抗-异环磷酰胺-卡铂-依托泊苷)与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤(DLBCL)。
机译:伏立诺他和利妥昔单抗治疗新诊断和复发/难治性惰性非霍奇金淋巴瘤的II期研究
机译:vorinostat和rituximab治疗新诊断和复发/难治性惰性非霍奇金淋巴瘤的II研究